# Biotech Intelligence Hub ‚Äî –î–µ—Ç–∞–ª—å–Ω–∞—è –∫–æ–Ω—Ü–µ–ø—Ü–∏—è –ø—Ä–æ–¥—É–∫—Ç–∞

> **–î–æ–∫—É–º–µ–Ω—Ç –¥–ª—è –ø—Ä–æ—Ä–∞–±–æ—Ç–∫–∏ –ø—Ä–æ–¥—É–∫—Ç–æ–≤–æ–π –∫–æ–Ω—Ü–µ–ø—Ü–∏–∏**  
> –°–æ–∑–¥–∞–Ω –Ω–∞ –æ—Å–Ω–æ–≤–µ –∞–Ω–∞–ª–∏–∑–∞ 615 –∏–¥–µ–π –∏–∑ –±–∞–∑—ã bioideas  
> –î–∞—Ç–∞: 2026-02-01

---

## 1. –í–ò–î–ï–ù–ò–ï –ü–†–û–î–£–ö–¢–ê

### 1.1 –°—É—Ç—å –∫–æ–Ω—Ü–µ–ø—Ü–∏–∏

**Biotech Intelligence Hub** ‚Äî –≤–µ—Ä—Ç–∏–∫–∞–ª—å–Ω–∞—è –ø–ª–∞—Ç—Ñ–æ—Ä–º–∞, –∫–æ—Ç–æ—Ä–∞—è –æ–±—ä–µ–¥–∏–Ω—è–µ—Ç:
- **Pipeline Intelligence** (—á—Ç–æ –º–µ–Ω—è–µ—Ç—Å—è –≤ R&D-–ø–∞–π–ø–ª–∞–π–Ω–∞—Ö)
- **Investor Briefs** (—Å—Ç—Ä—É–∫—Ç—É—Ä–∏—Ä–æ–≤–∞–Ω–Ω—ã–µ –≤—ã–∂–∏–º–∫–∏ –¥–ª—è –ø—Ä–∏–Ω—è—Ç–∏—è —Ä–µ—à–µ–Ω–∏–π)
- **Regulatory Tracking** (–º–æ–Ω–∏—Ç–æ—Ä–∏–Ω–≥ —Ä–µ–≥—É–ª—è—Ç–æ—Ä–Ω–æ–π –Ω–µ–æ–ø—Ä–µ–¥–µ–ª—ë–Ω–Ω–æ—Å—Ç–∏)
- **Catalyst & Deal Intelligence** (—Å–æ–±—ã—Ç–∏—è –∏ M&A-–∫–æ–Ω—Ç–µ–∫—Å—Ç)

### 1.2 –ö–ª—é—á–µ–≤–∞—è —Ü–µ–Ω–Ω–æ—Å—Ç—å

**–ï–¥–∏–Ω—ã–π –∏—Å—Ç–æ—á–Ω–∏–∫ –ø—Ä–∞–≤–¥—ã** –¥–ª—è –∏–Ω–≤–µ—Å—Ç–æ—Ä–æ–≤, –∞–Ω–∞–ª–∏—Ç–∏–∫–æ–≤ –∏ biotech-–∫–æ–º–∞–Ω–¥:
- Earnings calls ‚Üí Pipeline changes ‚Üí Regulatory updates ‚Üí Catalysts ‚Üí Deal signals

**–§–æ—Ä–º—É–ª–∞:**
```
Biotech Intelligence Hub = 
  Pipeline Brief Generator (—è–¥—Ä–æ) +
  Catalyst Radar (—Å–æ–±—ã—Ç–∏—è) +
  Regulatory Uncertainty Tracker (—Ä–∏—Å–∫–∏) +
  Deal Intelligence Layer (–∫–æ–Ω—Ç–µ–∫—Å—Ç M&A)
```

---

## 2. –Ø–î–†–û –ü–†–û–î–£–ö–¢–ê ‚Äî TIER 1 –ò–î–ï–ò

### 2.1 üéØ –Ø–ö–û–†–ù–ê–Ø –ò–î–ï–Ø: Earnings Call Pipeline Briefs

| –ü–æ–ª–µ | –°–æ–¥–µ—Ä–∂–∞–Ω–∏–µ |
|------|------------|
| **ID** | `idea_bac2082a6298_3_01` |
| **–ö–∞—Ç–µ–≥–æ—Ä–∏—è** | med_ai |
| **–ì–æ—Ä–∏–∑–æ–Ω—Ç** | 1-3 –≥–æ–¥–∞ |

#### –ü—Ä–æ–±–ª–µ–º–∞
–ê–Ω–∞–ª–∏—Ç–∏–∫–∏/–∏–Ω–≤–µ—Å—Ç–æ—Ä—ã –∏—Å–ø—ã—Ç—ã–≤–∞—é—Ç **–∏–Ω—Ñ–æ–ø–µ—Ä–µ–≥—Ä—É–∑–∫—É** –∏–∑-–∑–∞ –æ–¥–Ω–æ–≤—Ä–µ–º–µ–Ω–Ω—ã—Ö earnings calls –∏ –Ω–µ —É—Å–ø–µ–≤–∞—é—Ç –±—ã—Å—Ç—Ä–æ –∏–∑–≤–ª–µ—á—å –∫–ª—é—á–µ–≤—ã–µ –≤—ã–≤–æ–¥—ã, –æ—Å–æ–±–µ–Ω–Ω–æ –ø—Ä–æ –∏–∑–º–µ–Ω–µ–Ω–∏—è –≤ –ø–∞–π–ø–ª–∞–π–Ω–µ. –î–æ–ø–æ–ª–Ω–∏—Ç–µ–ª—å–Ω–æ —Ñ—Ä—É—Å—Ç—Ä–∏—Ä—É–µ—Ç, —á—Ç–æ –∑–Ω–∞—á–∏—Ç–µ–ª—å–Ω–∞—è —á–∞—Å—Ç—å –∑–≤–æ–Ω–∫–æ–≤ —É—Ö–æ–¥–∏—Ç –≤ —Ñ–∏–Ω–∞–Ω—Å–æ–≤—ã–µ –¥–µ—Ç–∞–ª–∏, –∫–æ—Ç–æ—Ä—ã–µ –≤–æ—Å–ø—Ä–∏–Ω–∏–º–∞—é—Ç—Å—è –∫–∞–∫ ¬´–Ω–µ –≤–∞–∂–Ω—ã–µ¬ª.

#### –†–µ—à–µ–Ω–∏–µ
**–í–µ–±-–ø—Ä–æ–¥—É–∫—Ç**: –∑–∞–≥—Ä—É–∑–∫–∞ —Ç—Ä–∞–Ω—Å–∫—Ä–∏–ø—Ç–∞/—Å—Å—ã–ª–∫–∏ ‚Üí —Å—Ç—Ä—É–∫—Ç—É—Ä–∏—Ä–æ–≤–∞–Ω–Ω–∞—è –≤—ã–∂–∏–º–∫–∞:
1. ¬´–ß—Ç–æ –Ω–æ–≤–æ–≥–æ –≤ –ø–∞–π–ø–ª–∞–π–Ω–µ¬ª (–ø–æ –ø—Ä–æ–≥—Ä–∞–º–º–∞–º/–∏–Ω–¥–∏–∫–∞—Ü–∏—è–º)
2. ¬´–ß—Ç–æ –∏–∑–º–µ–Ω–∏–ª–æ—Å—å —Å –ø—Ä–æ—à–ª–æ–≥–æ –∫–≤–∞—Ä—Ç–∞–ª–∞¬ª (–¥–æ–±–∞–≤–ª–µ–Ω–æ/—É–±—Ä–∞–Ω–æ/—Å–¥–≤–∏–Ω—É—Ç—ã —Å—Ä–æ–∫–∏/—Ä–∏—Å–∫–∏)
3. ¬´–°–∏–≥–Ω–∞–ª—ã/—Ä–∏—Å–∫–∏ –∏–∑ Q&A¬ª
4. –û—Ç–¥–µ–ª—å–Ω—ã–π –±–ª–æ–∫ ¬´—Ñ–∏–Ω–∞–Ω—Å—ã (–æ–ø—Ü–∏–æ–Ω–∞–ª—å–Ω–æ)¬ª

**–≠–∫—Å–ø–æ—Ä—Ç:** PDF/Notion/Slack

#### Wedge (—Ç–æ—á–∫–∞ –≤—Ö–æ–¥–∞)
–ë–µ—Å–ø–ª–∞—Ç–Ω—ã–π –≥–µ–Ω–µ—Ä–∞—Ç–æ—Ä 1-—Å—Ç—Ä–∞–Ω–∏—á–Ω–æ–≥–æ ¬´Pipeline Brief¬ª –ø–æ –æ–¥–Ω–æ–º—É —Ç—Ä–∞–Ω—Å–∫—Ä–∏–ø—Ç—É + –ø—É–±–ª–∏—á–Ω–∞—è –≥–∞–ª–µ—Ä–µ—è –ø—Ä–∏–º–µ—Ä–æ–≤ (–±–µ–∑ –Ω–µ–æ–±—Ö–æ–¥–∏–º–æ—Å—Ç–∏ –ª–æ–≥–∏–Ω–∞).

#### MVP (3-6 –º–µ—Å—è—Ü–µ–≤)
1. –ò–Ω–ø—É—Ç: –≤—Å—Ç–∞–≤–∫–∞ —Ç–µ–∫—Å—Ç–∞ —Ç—Ä–∞–Ω—Å–∫—Ä–∏–ø—Ç–∞
2. LLM-–ø–∞–π–ø–ª–∞–π–Ω —Å—É–º–º–∞—Ä–∏–∑–∞—Ü–∏–∏ —Å —Ñ–∏–∫—Å–∏—Ä–æ–≤–∞–Ω–Ω—ã–º —à–∞–±–ª–æ–Ω–æ–º (pipeline/Q&A/risks)
3. –°—Ä–∞–≤–Ω–µ–Ω–∏–µ –¥–≤—É—Ö —Ç—Ä–∞–Ω—Å–∫—Ä–∏–ø—Ç–æ–≤ –æ–¥–Ω–æ–π –∫–æ–º–ø–∞–Ω–∏–∏ –¥–ª—è ¬´change log¬ª
4. –≠–∫—Å–ø–æ—Ä—Ç –∏ —à–∞—Ä–∏–Ω–≥ —Å—Å—ã–ª–∫–æ–π
5. –ü—Ä–æ—Å—Ç–∞—è –æ—á–µ—Ä–µ–¥—å –∑–∞–¥–∞—á –∏ –∏—Å—Ç–æ—Ä–∏—è –¥–æ–∫—É–º–µ–Ω—Ç–æ–≤

#### Blue Ocean Thesis
–§–æ–∫—É—Å **–Ω–µ –Ω–∞ ¬´–æ–±—â–µ–º —Å–∞–º–º–∞—Ä–∏ –∑–≤–æ–Ω–∫–∞¬ª**, –∞ –Ω–∞ —É–∑–∫–æ–º, –ø–æ–≤—Ç–æ—Ä—è–µ–º–æ–º –∞—Ä—Ç–µ—Ñ–∞–∫—Ç–µ –¥–ª—è –ø—Ä–∏–Ω—è—Ç–∏—è —Ä–µ—à–µ–Ω–∏–π: –∏–∑–º–µ–Ω–µ–Ω–∏—è –≤ –ø–∞–π–ø–ª–∞–π–Ω–µ –∏ –∏—Ö –∏–Ω—Ç–µ—Ä–ø—Ä–µ—Ç–∞—Ü–∏—è, –ø—Ä–∏ —ç—Ç–æ–º —Ñ–∏–Ω–∞–Ω—Å–æ–≤—ã–µ –¥–µ—Ç–∞–ª–∏ —É–±—Ä–∞–Ω—ã –≤ –æ—Ç–¥–µ–ª—å–Ω—ã–π —Å–ª–æ–π.

#### Community Hook
–û—Ç–∫—Ä—ã—Ç—ã–π —à–∞–±–ª–æ–Ω ¬´Pipeline Brief¬ª + –º–∏–Ω–∏-–±–µ–Ω—á–º–∞—Ä–∫: –Ω–∞–±–æ—Ä –∞–Ω–æ–Ω–∏–º–∏–∑–∏—Ä–æ–≤–∞–Ω–Ω—ã—Ö —Ñ—Ä–∞–≥–º–µ–Ω—Ç–æ–≤ –∏ —ç—Ç–∞–ª–æ–Ω–Ω—ã—Ö —Ä–∞–∑–º–µ—Ç–æ–∫ ¬´—á—Ç–æ –∏–∑–º–µ–Ω–∏–ª–æ—Å—å¬ª, —á—Ç–æ–±—ã —Å–æ–æ–±—â–µ—Å—Ç–≤–æ —Å—Ä–∞–≤–Ω–∏–≤–∞–ª–æ –ø—Ä–æ–º–ø—Ç—ã/–º–æ–¥–µ–ª–∏.

#### –ú–æ–Ω–µ—Ç–∏–∑–∞—Ü–∏—è
–ü–æ–¥–ø–∏—Å–∫–∞ –¥–ª—è buy-side/IR/–∫–æ–Ω—Å–∞–ª—Ç–∏–Ω–≥–∞: –ø–∞–∫–µ—Ç –Ω–∞ N –∫–æ–º–ø–∞–Ω–∏–π/–º–µ—Å—è—Ü, –∫–æ–º–∞–Ω–¥–Ω—ã–µ —Ä–∞–±–æ—á–∏–µ –ø—Ä–æ—Å—Ç—Ä–∞–Ω—Å—Ç–≤–∞, –∞–ª–µ—Ä—Ç—ã –ø—Ä–∏ –ø–æ—è–≤–ª–µ–Ω–∏–∏ –Ω–æ–≤–æ–≥–æ —Ç—Ä–∞–Ω—Å–∫—Ä–∏–ø—Ç–∞/–æ–±–Ω–æ–≤–ª–µ–Ω–∏—è.

#### –ü–æ—Ç–µ–Ω—Ü–∏–∞–ª—å–Ω—ã–µ –ø–æ–∫—É–ø–∞—Ç–µ–ª–∏ (acquirers)
- –ü–ª–∞—Ç—Ñ–æ—Ä–º—ã —Ñ–∏–Ω–∞–Ω—Å–æ–≤–æ–π –∞–Ω–∞–ª–∏—Ç–∏–∫–∏/–¥–∞–Ω–Ω—ã—Ö
- –ü—Ä–æ–≤–∞–π–¥–µ—Ä—ã IR/–∫–æ—Ä–ø–æ—Ä–∞—Ç–∏–≤–Ω—ã—Ö –∫–æ–º–º—É–Ω–∏–∫–∞—Ü–∏–π
- –ò–Ω—Å—Ç—Ä—É–º–µ–Ω—Ç—ã –¥–ª—è research/knowledge management –≤ —Ñ–æ–Ω–¥–∞—Ö

#### –ö–ª—é—á–µ–≤—ã–µ —Ä–∏—Å–∫–∏
- –ö–∞—á–µ—Å—Ç–≤–æ —Ç—Ä–∞–Ω—Å–∫—Ä–∏–ø—Ç–æ–≤ –∏ –Ω–µ–æ–¥–Ω–æ–∑–Ω–∞—á–Ω–æ—Å—Ç—å —Ñ–æ—Ä–º—É–ª–∏—Ä–æ–≤–æ–∫
- –û–∂–∏–¥–∞–Ω–∏—è –ø–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª–µ–π –∫ ¬´—Ç–æ—á–Ω–æ—Å—Ç–∏¬ª –∏–Ω—Ç–µ—Ä–ø—Ä–µ—Ç–∞—Ü–∏–∏
- –†–∞–∑–Ω—ã–µ —Ñ–æ—Ä–º–∞—Ç—ã –∑–≤–æ–Ω–∫–æ–≤ —É—Å–ª–æ–∂–Ω—è—é—Ç —É–Ω–∏—Ñ–∏–∫–∞—Ü–∏—é

---

### 2.2 Data-First IR Kit –¥–ª—è biotech

| –ü–æ–ª–µ | –°–æ–¥–µ—Ä–∂–∞–Ω–∏–µ |
|------|------------|
| **ID** | `idea_bac2082a6298_2_01` |
| **–ö–∞—Ç–µ–≥–æ—Ä–∏—è** | biotech_ops |
| **–ì–æ—Ä–∏–∑–æ–Ω—Ç** | 1-3 –≥–æ–¥–∞ |

#### –ü—Ä–æ–±–ª–µ–º–∞
–£ —Ä–∞–Ω–Ω–∏—Ö/development-stage –∫–æ–º–ø–∞–Ω–∏–π earnings calls —á–∞—Å—Ç–æ **–¥–ª–∏–Ω–Ω—ã–µ, –ø–æ–≤—Ç–æ—Ä—è—é—â–∏–µ—Å—è –∏ —Ä–µ—Ç—Ä–æ—Å–ø–µ–∫—Ç–∏–≤–Ω—ã–µ**; Q&A –Ω–µ—Ä–µ–¥–∫–æ –Ω–µ –¥–æ–±–∞–≤–ª—è–µ—Ç –ø–æ–Ω–∏–º–∞–Ω–∏—è. –ü—Ä–∏ —ç—Ç–æ–º –æ—Ç–∫–∞–∑ –æ—Ç —Ä–µ–≥—É–ª—è—Ä–Ω—ã—Ö calls –º–æ–∂–µ—Ç –ø—Ä–∏–≤–µ—Å—Ç–∏ –∫ –ø–æ—Ç–µ—Ä–µ –≤–Ω–∏–º–∞–Ω–∏—è —Ä—ã–Ω–∫–∞/–∞–Ω–∞–ª–∏—Ç–∏–∫–æ–≤ –∏ —Å—Ç–∞—Ç—å ¬´non-entity¬ª.

#### –†–µ—à–µ–Ω–∏–µ
–í–µ–±-–ø—Ä–æ–¥—É–∫—Ç –¥–ª—è –ø–µ—Ä–µ—Ö–æ–¥–∞ –Ω–∞ **¬´data-release-first¬ª –∫–æ–º–º—É–Ω–∏–∫–∞—Ü–∏–∏**:
1. –®–∞–±–ª–æ–Ω—ã –∏ –≥–µ–Ω–µ—Ä–∞—Ü–∏—è –∫–æ—Ä–æ—Ç–∫–∏—Ö –∞–ø–¥–µ–π—Ç–æ–≤ –≤–æ–∫—Ä—É–≥ –∫–ª—é—á–µ–≤—ã—Ö data releases
2. –ö–≤–∞—Ä—Ç–∞–ª—å–Ω—ã–µ –≤–æ–ø—Ä–æ—Å—ã (cash runway, —Å—Ç–∞—Ç—É—Å –ø—Ä–æ–≥—Ä–∞–º–º) –∑–∞–∫—Ä—ã–≤–∞—é—Ç—Å—è —Å—Ç—Ä—É–∫—Ç—É—Ä–∏—Ä–æ–≤–∞–Ω–Ω—ã–º –ø—Ä–µ—Å—Å-—Ä–µ–ª–∏–∑–æ–º
3. –ê–≤—Ç–æ-—Å–±–æ—Ä–∫–∞ –º–∞—Ç–µ—Ä–∏–∞–ª–æ–≤: 1-page summary, FAQ –¥–ª—è –∞–Ω–∞–ª–∏—Ç–∏–∫–æ–≤, —Å–ø–∏—Å–æ–∫ ¬´—á—Ç–æ –∏–∑–º–µ–Ω–∏–ª–æ—Å—å —Å –ø—Ä–æ—à–ª–æ–≥–æ –∞–ø–¥–µ–π—Ç–∞¬ª

#### Wedge
–ì–µ–Ω–µ—Ä–∞—Ç–æ—Ä ¬´2-—Å—Ç—Ä–∞–Ω–∏—á–Ω–æ–≥–æ data-driven update¬ª –∏–∑ —á–µ—Ä–Ω–æ–≤–∏–∫–∞/–ø—Ä–µ—Å—Å-—Ä–µ–ª–∏–∑–∞ + —á–µ–∫–ª–∏—Å—Ç –æ–±—è–∑–∞—Ç–µ–ª—å–Ω—ã—Ö –∫–≤–∞—Ä—Ç–∞–ª—å–Ω—ã—Ö disclosure.

#### MVP
1. –§–æ—Ä–º—ã –≤–≤–æ–¥–∞ (key data points, –ø—Ä–æ–≥—Ä–∞–º–º—ã, –≤–µ—Ö–∏)
2. LLM-–≥–µ–Ω–µ—Ä–∞—Ü–∏—è –ø–∞–∫–µ—Ç–∞: one-page, FAQ, ¬´—á—Ç–æ –∏–∑–º–µ–Ω–∏–ª–æ—Å—å¬ª
3. –í–µ—Ä—Å–∏–æ–Ω–∏—Ä–æ–≤–∞–Ω–∏–µ –ø–æ –∫–≤–∞—Ä—Ç–∞–ª–∞–º
4. –≠–∫—Å–ø–æ—Ä—Ç –≤ PDF/DOCX/Notion
5. –ü—É–±–ª–∏—á–Ω—ã–π —à–∞–±–ª–æ–Ω –∏ –ø—Ä–∏–º–µ—Ä—ã

#### –°–∏–Ω–µ—Ä–≥–∏—è —Å —è–¥—Ä–æ–º
**–î–æ–ø–æ–ª–Ω—è–µ—Ç earnings-based –ø–æ–¥—Ö–æ–¥** –∫–æ–Ω—Ç–µ–Ω—Ç–æ–º –º–µ–∂–¥—É earnings: data releases, milestones, –æ–ø–µ—Ä–∞—Ç–∏–≤–Ω—ã–µ –∞–ø–¥–µ–π—Ç—ã.

---

### 2.3 Biotech Catalyst Radar

| –ü–æ–ª–µ | –°–æ–¥–µ—Ä–∂–∞–Ω–∏–µ |
|------|------------|
| **ID** | `idea_bac2082a6298_2_02` |
| **–ö–∞—Ç–µ–≥–æ—Ä–∏—è** | community |
| **–ì–æ—Ä–∏–∑–æ–Ω—Ç** | 1-3 –≥–æ–¥–∞ |

#### –ü—Ä–æ–±–ª–µ–º–∞
–ò–Ω–≤–µ—Å—Ç–æ—Ä—ã **–ø–æ—á—Ç–∏ –Ω–µ –∏–Ω—Ç–µ—Ä–µ—Å—É—é—Ç—Å—è –∫–∞—Ç–∞–ª–∏–∑–∞—Ç–æ—Ä–∞–º–∏ 2026 –≥–æ–¥–∞** –∏ —Ñ–æ–∫—É—Å–∏—Ä—É—é—Ç—Å—è –Ω–∞ –±–ª–∏–∂–∞–π—à–∏—Ö 3‚Äì4 –º–µ—Å—è—Ü–∞—Ö; –ø—Ä–∏ —ç—Ç–æ–º —Å–∏–ª—å–Ω—ã–µ –º–∞–∫—Ä–æ-–¥–∏—Å—Ç—Ä–∞–∫—Ü–∏–∏ —Å–æ–∑–¥–∞—é—Ç —Å–ª–µ–ø—ã–µ –∑–æ–Ω—ã.

#### –†–µ—à–µ–Ω–∏–µ
**–õ–µ–Ω—Ç–∞/–∫–∞–ª–µ–Ω–¥–∞—Ä—å –±–ª–∏–∂–∞–π—à–∏—Ö –∫–∞—Ç–∞–ª–∏–∑–∞—Ç–æ—Ä–æ–≤ (3‚Äì4 –º–µ—Å—è—Ü–∞)** —Å –∫—Ä–∞—Ç–∫–∏–º–∏ –∫–∞—Ä—Ç–æ—á–∫–∞–º–∏:
- –¢–∏–ø —Å–æ–±—ã—Ç–∏—è (data release/—Ä–µ–≥—É–ª—è—Ç–æ—Ä–Ω—ã–π –∞–ø–¥–µ–π—Ç/–∫–æ—Ä–ø–æ—Ä–∞—Ç–∏–≤–Ω—ã–π –∞–ø–¥–µ–π—Ç)
- ¬´–ü–æ—á–µ–º—É —ç—Ç–æ –±–∏–Ω–∞—Ä–Ω–æ¬ª
- –ß—Ç–æ –∫–æ–º–ø–∞–Ω–∏—è –æ–±–µ—â–∞–ª–∞ —Ä–∞–Ω–µ–µ
- –ê–ª–µ—Ä—Ç—ã –∏ –ø–µ—Ä—Å–æ–Ω–∞–ª—å–Ω—ã–µ watchlists

–î–ª—è –∫–æ–º–ø–∞–Ω–∏–π ‚Äî —Ä–µ–∂–∏–º ¬´publisher¬ª: –±—ã—Å—Ç—Ä–æ –ø—É–±–ª–∏–∫–æ–≤–∞—Ç—å —Å—Ç—Ä—É–∫—Ç—É—Ä–∏—Ä–æ–≤–∞–Ω–Ω—ã–µ –∞–ø–¥–µ–π—Ç—ã.

#### Wedge
–ï–∂–µ–Ω–µ–¥–µ–ª—å–Ω–∞—è email-—Ä–∞—Å—Å—ã–ª–∫–∞/–ª–µ–Ω—Ç–∞ **¬´Next 90 days in biotech¬ª** —Å –ø–µ—Ä—Å–æ–Ω–∞–ª–∏–∑–∞—Ü–∏–µ–π –ø–æ watchlist –∏ –∞–≤—Ç–æ-–≤—ã–∂–∏–º–∫–æ–π ¬´—á—Ç–æ –∏–∑–º–µ–Ω–∏–ª–æ—Å—å —Å –ø—Ä–æ—à–ª–æ–π –Ω–µ–¥–µ–ª–∏¬ª.

#### MVP
1. –†—É—á–Ω–æ–µ –¥–æ–±–∞–≤–ª–µ–Ω–∏–µ —Å–æ–±—ã—Ç–∏–π (–ø–æ–∫–∞ –±–µ–∑ –ø–∞—Ä—Å–∏–Ω–≥–∞)
2. –ö–∞—Ä—Ç–æ—á–∫–∞ —Å–æ–±—ã—Ç–∏—è: —Ç–∏–ø, –¥–∞—Ç–∞, –∫–æ–º–ø–∞–Ω–∏—è, ¬´–ø–æ—á–µ–º—É –≤–∞–∂–Ω–æ¬ª
3. –ü–µ—Ä—Å–æ–Ω–∞–ª—å–Ω—ã–µ watchlist –∏ email/Slack-–∞–ª–µ—Ä—Ç—ã
4. –ü—É–±–ª–∏—á–Ω–∞—è –ª–µ–Ω—Ç–∞ ¬´Next 90 days¬ª
5. –†–µ–∂–∏–º publisher –¥–ª—è –∫–æ–º–ø–∞–Ω–∏–π (–∑–∞—è–≤–∫–∞)

#### –°–∏–Ω–µ—Ä–≥–∏—è —Å —è–¥—Ä–æ–º
**Calendar layer** –¥–ª—è Pipeline Briefs: –ø–æ—Å–ª–µ earnings –ø–æ—è–≤–ª—è–µ—Ç—Å—è –∫–∞—Ä—Ç–æ—á–∫–∞ ¬´—Å–ª–µ–¥—É—é—â–∏–π catalyst —á–µ—Ä–µ–∑ N –¥–Ω–µ–π¬ª.

---

### 2.4 Quarterly Launch Brief Generator

| –ü–æ–ª–µ | –°–æ–¥–µ—Ä–∂–∞–Ω–∏–µ |
|------|------------|
| **ID** | `idea_433066c16b44_4_02` |
| **–ö–∞—Ç–µ–≥–æ—Ä–∏—è** | med_ai |
| **–ì–æ—Ä–∏–∑–æ–Ω—Ç** | 1-3 –≥–æ–¥–∞ |

#### –ü—Ä–æ–±–ª–µ–º–∞
–ö–æ–≥–¥–∞ —Ñ–æ–∫—É—Å –Ω–∞ –∫–≤–∞—Ä—Ç–∞–ª—å–Ω—ã—Ö –ø—Ä–æ–¥–∞–∂–∞—Ö –∏ –¥–∏–Ω–∞–º–∏–∫–µ –∑–∞–ø—É—Å–∫–æ–≤, –∫–æ–º–∞–Ω–¥–∞–º –Ω—É–∂–Ω–æ **–±—ã—Å—Ç—Ä–æ –∏ –æ–¥–∏–Ω–∞–∫–æ–≤–æ –æ—Ñ–æ—Ä–º–ª—è—Ç—å –∞–ø–¥–µ–π—Ç—ã** –ø–æ –∫–∞–∂–¥–æ–º—É –ø—Ä–µ–ø–∞—Ä–∞—Ç—É/–∑–∞–ø—É—Å–∫—É.

#### –†–µ—à–µ–Ω–∏–µ
**–í–µ–±-—Ñ–æ—Ä–º–∞ + LLM-–∞—Å—Å–∏—Å—Ç–µ–Ω—Ç**: –ø–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª—å –≤–≤–æ–¥–∏—Ç –∫–ª—é—á–µ–≤—ã–µ –ø—É–Ω–∫—Ç—ã –∫–≤–∞—Ä—Ç–∞–ª–∞ (–ø—Ä–æ–¥–∞–∂–∏, –¥–∏–Ω–∞–º–∏–∫–∞ –∑–∞–ø—É—Å–∫–∞, —á—Ç–æ –∏–∑–º–µ–Ω–∏–ª–æ—Å—å), –∞ —Å–∏—Å—Ç–µ–º–∞ –≥–µ–Ω–µ—Ä–∏—Ä—É–µ—Ç —Å—Ç—Ä—É–∫—Ç—É—Ä–∏—Ä–æ–≤–∞–Ω–Ω—ã–π –±—Ä–∏—Ñ:
- Summary
- –î—Ä–∞–π–≤–µ—Ä—ã
- –†–∏—Å–∫–∏
- –í–æ–ø—Ä–æ—Å—ã –Ω–∞ —Å–ª–µ–¥—É—é—â–∏–π –∫–≤–∞—Ä—Ç–∞–ª

#### MVP
1. –ö–æ–Ω—Å—Ç—Ä—É–∫—Ç–æ—Ä —à–∞–±–ª–æ–Ω–æ–≤ –±—Ä–∏—Ñ–∞ (–ø–æ–ª—è + —Å–µ–∫—Ü–∏–∏)
2. –ì–µ–Ω–µ—Ä–∞—Ü–∏—è —Ç–µ–∫—Å—Ç–∞ –∏–∑ –≤–≤–µ–¥—ë–Ω–Ω—ã—Ö –±—É–ª–ª–µ—Ç–æ–≤ (LLM) –∏ –∫–æ–Ω—Ç—Ä–æ–ª—å –¥–ª–∏–Ω—ã
3. –ò—Å—Ç–æ—Ä–∏—è –≤–µ—Ä—Å–∏–π –ø–æ –∫–≤–∞—Ä—Ç–∞–ª–∞–º –¥–ª—è –æ–¥–Ω–æ–≥–æ –∑–∞–ø—É—Å–∫–∞
4. –≠–∫—Å–ø–æ—Ä—Ç (PDF/DOCX) –∏ —à–∞—Ä–∏–Ω–≥ —Å—Å—ã–ª–∫–æ–π

#### –°–∏–Ω–µ—Ä–≥–∏—è —Å —è–¥—Ä–æ–º
**Post-launch layer**: Pipeline Briefs –¥–ª—è development-stage ‚Üí Launch Briefs –¥–ª—è commercial-stage.

---

### 2.5 Pipeline Gap Radar

| –ü–æ–ª–µ | –°–æ–¥–µ—Ä–∂–∞–Ω–∏–µ |
|------|------------|
| **ID** | `idea_mna_pipeline_radar_001` |
| **–ö–∞—Ç–µ–≥–æ—Ä–∏—è** | biotech_ops |
| **–ì–æ—Ä–∏–∑–æ–Ω—Ç** | 1-3 –≥–æ–¥–∞ |

#### –ü—Ä–æ–±–ª–µ–º–∞
–§–∞—Ä–º–∞ —Ä–µ–≥—É–ª—è—Ä–Ω–æ —Å—Ç–∞–ª–∫–∏–≤–∞–µ—Ç—Å—è —Å –ø—Ä–æ–≤–∞–ª–∞–º–∏ –≤–Ω—É—Ç—Ä–µ–Ω–Ω–µ–π —Ä–∞–∑—Ä–∞–±–æ—Ç–∫–∏ –∏ –≤—ã–Ω—É–∂–¥–µ–Ω–∞ –ø–æ–∫—É–ø–∞—Ç—å/–∏–Ω-–ª–∏—Ü–µ–Ω–∑–∏—Ä–æ–≤–∞—Ç—å –∞–∫—Ç–∏–≤—ã. –ö–æ–º–∞–Ω–¥–∞–º BD/strategy —Å–ª–æ–∂–Ω–æ –±—ã—Å—Ç—Ä–æ –∏ —Å–∏—Å—Ç–µ–º–Ω–æ –æ—Ç—Å–ª–µ–∂–∏–≤–∞—Ç—å, **–≥–¥–µ –∏–º–µ–Ω–Ω–æ —Ñ–æ—Ä–º–∏—Ä—É—é—Ç—Å—è ¬´–ø–∞–π–ø–ª–∞–π–Ω-–¥—ã—Ä—ã¬ª**.

#### –†–µ—à–µ–Ω–∏–µ
**–í–µ–±-–ø—Ä–æ–¥—É–∫—Ç —Å –¥–∞—à–±–æ—Ä–¥–∞–º–∏**:
1. –¢—Ä–µ–∫–∏–Ω–≥ —Ç–µ–º–ø–∞ M&A (—á–∞—Å—Ç–æ—Ç–∞/–∫—Ä—É–ø–Ω–æ—Å—Ç—å)
2. –ö–∞—Ä—Ç–∞ ¬´–ø–æ–ø–æ–ª–Ω–µ–Ω–∏—è –ø–∞–π–ø–ª–∞–π–Ω–∞¬ª (–∫–∞–∫–∏–µ —Ç–∏–ø—ã –∞–∫—Ç–∏–≤–æ–≤/–ø–ª–∞—Ç—Ñ–æ—Ä–º —á–∞—â–µ –ø–æ–∫—É–ø–∞—é—Ç)
3. –ê–ª–µ—Ä—Ç—ã –ø–æ ¬´—Å–µ—Ä–∏—è–º —Å–¥–µ–ª–æ–∫¬ª –∏ —Å–º–µ–Ω–µ —Ñ–æ–∫—É—Å–∞
4. –ó–∞–º–µ—Ç–∫–∏/–æ–±–æ—Å–Ω–æ–≤–∞–Ω–∏—è –¥–ª—è BD

#### Wedge
–ï–∂–µ–Ω–µ–¥–µ–ª—å–Ω—ã–π **¬´M&A streak¬ª digest** + –∞–ª–µ—Ä—Ç—ã –ø–æ –∫—Ä—É–ø–Ω—ã–º —Å–¥–µ–ª–∫–∞–º –∏ –ø–æ —Ç–µ–º–∞–º, –≥–¥–µ –∞–∫—Ç–∏–≤—ã –±—ã—Å—Ç—Ä–æ ¬´—Å—Ö–≤–∞—Ç—ã–≤–∞—é—Ç—Å—è¬ª.

#### MVP
1. –ü–∞—Ä—Å–µ—Ä/–∞–≥—Ä–µ–≥–∞—Ç–æ—Ä –Ω–æ–≤–æ—Å—Ç–µ–π –≤ —Ä—É—á–Ω–æ–º —Ä–µ–∂–∏–º–µ + –ø–æ–ª—É–∞–≤—Ç–æ–º–∞—Ç–∏—á–µ—Å–∫–∞—è —Ä–∞–∑–º–µ—Ç–∫–∞ —Å–¥–µ–ª–æ–∫
2. –ü—Ä–æ—Å—Ç–∞—è —Ç–∞–∫—Å–æ–Ω–æ–º–∏—è ¬´–ø–ª–∞—Ç—Ñ–æ—Ä–º–∞ vs –∞–∫—Ç–∏–≤¬ª –∏ ¬´—Ä–∞–Ω–Ω—è—è —á–∞—Å—Ç—å –ø–∞–π–ø–ª–∞–π–Ω–∞¬ª
3. –î–∞—à–±–æ—Ä–¥ (—Ç–∞–±–ª–∏—Ü–∞/–≥—Ä–∞—Ñ–∏–∫–∏) + email/Slack-–∞–ª–µ—Ä—Ç—ã
4. –≠–∫—Å–ø–æ—Ä—Ç –≤ CSV/Notion –¥–ª—è BD-–∫–æ–º–∞–Ω–¥

#### –°–∏–Ω–µ—Ä–≥–∏—è —Å —è–¥—Ä–æ–º
**Strategic context layer**: Pipeline Briefs –ø–æ–∫–∞–∑—ã–≤–∞—é—Ç –∏–∑–º–µ–Ω–µ–Ω–∏—è ‚Üí Gap Radar –ø–æ–∫–∞–∑—ã–≤–∞–µ—Ç, –ø–æ—á–µ–º—É —ç—Ç–æ –≤–∞–∂–Ω–æ –¥–ª—è M&A.

---

### 2.6 Patent Cliff ‚Üí M&A Map

| –ü–æ–ª–µ | –°–æ–¥–µ—Ä–∂–∞–Ω–∏–µ |
|------|------------|
| **ID** | `idea_patent_cliff_pipeline_map` |
| **–ö–∞—Ç–µ–≥–æ—Ä–∏—è** | bioinformatics |
| **–ì–æ—Ä–∏–∑–æ–Ω—Ç** | 3-5 –ª–µ—Ç |

#### –ü—Ä–æ–±–ª–µ–º–∞
–î–∞–≤–ª–µ–Ω–∏–µ LOE/patent cliffs –∏ –Ω–µ–¥–æ—Å—Ç–∞—Ç–æ–∫ –æ—Ä–≥–∞–Ω–∏—á–µ—Å–∫–æ–≥–æ —Ä–æ—Å—Ç–∞ –ø–æ–¥—Ç–∞–ª–∫–∏–≤–∞—é—Ç —Ñ–∞—Ä–º—É –∫ –ø—Ä–∏–æ–±—Ä–µ—Ç–µ–Ω–∏—è–º. –ù–æ –¥–ª—è –Ω–µ–±–æ–ª—å—à–∏—Ö –∫–æ–º–∞–Ω–¥ —Å–ª–æ–∂–Ω–æ –ø–µ—Ä–µ–≤–µ—Å—Ç–∏ —ç—Ç–æ –≤ –ø—Ä–∞–∫—Ç–∏–∫—É: **–∫–æ–º—É –∏ —Å –∫–∞–∫–∏–º —Ç–µ–∑–∏—Å–æ–º –ø–∏—Å–∞—Ç—å**.

#### –†–µ—à–µ–Ω–∏–µ
**–í–µ–±-–ø—Ä–æ–¥—É–∫—Ç ¬´Buyer Need Map¬ª**:
- –°–ø–∏—Å–æ–∫ –ø–æ–∫—É–ø–∞—Ç–µ–ª—å—Å–∫–∏—Ö –¥—Ä–∞–π–≤–µ—Ä–æ–≤ (LOE/patent cliffs, –Ω–µ–æ–±—Ö–æ–¥–∏–º–æ—Å—Ç—å –ø–æ–∫—É–ø–∞—Ç—å –≤—ã—Ä—É—á–∫—É)
- –°–≤—è–∑—å —Å —Å–æ–±—Å—Ç–≤–µ–Ω–Ω—ã–º –∞–∫—Ç–∏–≤–æ–º/–∫–∞—Ç–µ–≥–æ—Ä–∏–µ–π —á–µ—Ä–µ–∑ —Å—Ç—Ä—É–∫—Ç—É—Ä–∏—Ä–æ–≤–∞–Ω–Ω—ã–µ —Ç–µ–∑–∏—Å—ã
- Outreach-–ø–∞–∫–µ—Ç—ã

#### Wedge
–ö–æ–Ω—Å—Ç—Ä—É–∫—Ç–æ—Ä **¬´Outreach pack¬ª**: 1-—Å—Ç—Ä–∞–Ω–∏—á–Ω—ã–π —Ç–µ–∑–∏—Å ¬´–ø–æ—á–µ–º—É —Å–µ–π—á–∞—Å¬ª + 5 –≤–∞—Ä–∏–∞–Ω—Ç–æ–≤ –ø–∏—Å—å–º–∞ –ø–æ–¥ —Ä–∞–∑–Ω—ã–µ —Ä–æ–ª–∏.

#### –°–∏–Ω–µ—Ä–≥–∏—è —Å —è–¥—Ä–æ–º
**BD enablement layer**: Pipeline –∏–∑–º–µ–Ω–µ–Ω–∏—è + Patent Cliff –∫–æ–Ω—Ç–µ–∫—Å—Ç = actionable outreach.

---

### 2.7 Pipeline Capital Allocator

| –ü–æ–ª–µ | –°–æ–¥–µ—Ä–∂–∞–Ω–∏–µ |
|------|------------|
| **ID** | `idea_biotech_capital_allocator` |
| **–ö–∞—Ç–µ–≥–æ—Ä–∏—è** | biotech_ops |
| **–ì–æ—Ä–∏–∑–æ–Ω—Ç** | 1-3 –≥–æ–¥–∞ |

#### –ü—Ä–æ–±–ª–µ–º–∞
–î–µ–Ω—å–≥–∏ **¬´–ø–µ—Ä–µ–∫–∞—Ç—ã–≤–∞—é—Ç¬ª –∏–∑ –æ–¥–Ω–æ–≥–æ –ø—Ä–æ–≤–∞–ª–∞ –≤ —Å–ª–µ–¥—É—é—â–∏–π –∞–∫—Ç–∏–≤ –ø–∞–π–ø–ª–∞–π–Ω–∞**, —á—Ç–æ –ø–ª–æ—Ö–æ –¥–ª—è —Ü–µ–Ω–Ω—ã—Ö –¥–µ–Ω–µ–∂–Ω—ã—Ö —Ä–µ–∑–µ—Ä–≤–æ–≤. –î–∏—Å—Ü–∏–ø–ª–∏–Ω–∞ –∞–ª–ª–æ–∫–∞—Ü–∏–∏ —Å—Ç–∞–Ω–æ–≤–∏—Ç—Å—è –∫–æ–Ω–∫—É—Ä–µ–Ω—Ç–Ω—ã–º –ø—Ä–µ–∏–º—É—â–µ—Å—Ç–≤–æ–º.

#### –†–µ—à–µ–Ω–∏–µ
**–í–µ–±-–ø—Ä–æ–¥—É–∫—Ç –¥–ª—è —É–ø—Ä–∞–≤–ª–µ–Ω–∏—è —Ä–µ—à–µ–Ω–∏—è–º–∏ –ø–æ –ø–∞–π–ø–ª–∞–π–Ω—É**:
- –†–µ–µ—Å—Ç—Ä –∞–∫—Ç–∏–≤–æ–≤
- ¬´Decision log¬ª (—á—Ç–æ —Ä–µ—à–∏–ª–∏ –∏ –ø–æ—á–µ–º—É)
- –ü—Ä–∞–≤–∏–ª–∞ stop/go
- –ü—Ä–∏–≤—è–∑–∫–∞ –∫ –≤–µ—Ö–∞–º –∏ –±—é–¥–∂–µ—Ç—É
- –ê–≤—Ç–æ-—Å–≤–æ–¥–∫–∏ –¥–ª—è –±–æ—Ä–¥–∞

#### Wedge
**Decision-log –¥–ª—è –±–æ—Ä–¥–∞**: —à–∞–±–ª–æ–Ω –ø—Ä–æ—Ç–æ–∫–æ–ª–∞ —Ä–µ—à–µ–Ω–∏—è (–≥–∏–ø–æ—Ç–µ–∑–∞ ‚Üí –∫—Ä–∏—Ç–µ—Ä–∏–∏ —É—Å–ø–µ—Ö–∞ ‚Üí –±—é–¥–∂–µ—Ç ‚Üí –¥–∞—Ç–∞ –ø–µ—Ä–µ—Å–º–æ—Ç—Ä–∞ ‚Üí —É—Å–ª–æ–≤–∏—è –æ—Å—Ç–∞–Ω–æ–≤–∫–∏) + –Ω–∞–ø–æ–º–∏–Ω–∞–Ω–∏—è –æ –ø–µ—Ä–µ—Å–º–æ—Ç—Ä–µ.

#### –°–∏–Ω–µ—Ä–≥–∏—è —Å —è–¥—Ä–æ–º
**Internal governance layer**: Pipeline Briefs (–≤–Ω–µ—à–Ω–∏–µ) + Capital Allocator (–≤–Ω—É—Ç—Ä–µ–Ω–Ω–∏–µ —Ä–µ—à–µ–Ω–∏—è).

---

## 3. –†–ê–°–®–ò–†–ï–ù–ò–ï –ü–†–û–î–£–ö–¢–ê ‚Äî TIER 2 –ò–î–ï–ò

### 3.1 –ö–õ–ê–°–¢–ï–†: Investor Intelligence

#### 3.1.1 Generalist‚ÜíBiotech Briefing
**ID:** `idea_generalist_biotech_briefing`

**–ü—Ä–æ–±–ª–µ–º–∞:** Generalist-–∏–Ω–≤–µ—Å—Ç–æ—Ä—ã –Ω–∞—á–∏–Ω–∞—é—Ç –ø—Ä–æ—è–≤–ª—è—Ç—å –∏–Ω—Ç–µ—Ä–µ—Å –∫ biotech, –Ω–æ –∏–º –Ω–µ —Ö–≤–∞—Ç–∞–µ—Ç —Å—Ç—Ä—É–∫—Ç—É—Ä–∏—Ä–æ–≤–∞–Ω–Ω–æ–≥–æ –æ–Ω–±–æ—Ä–¥–∏–Ω–≥–∞.

**–†–µ—à–µ–Ω–∏–µ:** –í–µ–±-–ø—Ä–æ–¥—É–∫—Ç, –∫–æ—Ç–æ—Ä—ã–π –ø—Ä–µ–≤—Ä–∞—â–∞–µ—Ç ¬´—Ä–∞–∑–±–æ—Ä –∫–æ–º–ø–∞–Ω–∏–∏/–∫–µ–π—Å–∞¬ª –≤ —Å—Ç—Ä—É–∫—Ç—É—Ä–∏—Ä–æ–≤–∞–Ω–Ω—ã–π –±—Ä–∏—Ñ: —Ç–µ–∑–∏—Å—ã, —Å–ø–∏—Å–æ–∫ –≤–æ–ø—Ä–æ—Å–æ–≤ –¥–ª—è diligence, –∫–∞—Ä—Ç–∞ —Ä–∏—Å–∫–æ–≤.

**Wedge:** –ì–µ–Ω–µ—Ä–∞—Ç–æ—Ä ¬´call prep sheet¬ª –¥–ª—è –∑–≤–æ–Ω–∫–∞ —Å biotech-–º–µ–Ω–µ–¥–∂–º–µ–Ω—Ç–æ–º.

**–°–∏–Ω–µ—Ä–≥–∏—è:** –û–Ω–±–æ—Ä–¥–∏–Ω–≥ –¥–ª—è –Ω–æ–≤—ã—Ö –ø–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª–µ–π –ø–ª–∞—Ç—Ñ–æ—Ä–º—ã.

---

#### 3.1.2 M&A Readiness Copilot
**ID:** `idea_biotech_ma_readiness`

**–ü—Ä–æ–±–ª–µ–º–∞:** –ü–æ—Å–ª–µ —É—Å–ø–µ—à–Ω–æ–≥–æ –∑–∞–ø—É—Å–∫–∞ –ø—Ä–µ–ø–∞—Ä–∞—Ç–∞ biotech –Ω—É–∂–Ω–æ –ø–æ–∫–∞–∑–∞—Ç—å ¬´—á—Ç–æ –¥–∞–ª—å—à–µ¬ª, –¥–æ–ª–≥–æ—Å—Ä–æ—á–Ω—É—é —Å—Ç—Ä–∞—Ç–µ–≥–∏—é –∏ M&A-–≥–æ—Ç–æ–≤–Ω–æ—Å—Ç—å.

**–†–µ—à–µ–Ω–∏–µ:** –í–µ–±-–ø—Ä–æ–¥—É–∫—Ç —Å —à–∞–±–ª–æ–Ω–∞–º–∏ –∏ LLM-–≤–æ—Ä–∫—Ñ–ª–æ—É: –≥–µ–Ω–µ—Ä–∏—Ä—É–µ—Ç ¬´Next Chapter Pack¬ª (—Å—Ç—Ä–∞—Ç–µ–≥–∏—è, –≤–∞—Ä–∏–∞–Ω—Ç—ã BD/M&A, roadmap, Q&A –¥–ª—è diligence).

**Wedge:** –ì–µ–Ω–µ—Ä–∞—Ç–æ—Ä ¬´Next Chapter Pack¬ª (10‚Äì15 —Å–ª–∞–π–¥–æ–≤ + 1-pager).

**–°–∏–Ω–µ—Ä–≥–∏—è:** –î–ª—è –∫–æ–º–ø–∞–Ω–∏–π, –∫–æ—Ç–æ—Ä—ã–µ —É–∂–µ –∏—Å–ø–æ–ª—å–∑—É—é—Ç Pipeline Briefs ‚Äî —Å–ª–µ–¥—É—é—â–∏–π —à–∞–≥.

---

#### 3.1.3 Opacity Discount Monitor
**ID:** `idea_opacity_discount_monitor`

**–ü—Ä–æ–±–ª–µ–º–∞:** –ù–µ–ø—Ä–æ–∑—Ä–∞—á–Ω–æ—Å—Ç—å –º–µ–Ω–µ–¥–∂–º–µ–Ω—Ç–∞ –≤–æ—Å–ø—Ä–∏–Ω–∏–º–∞–µ—Ç—Å—è –Ω–µ–≥–∞—Ç–∏–≤–Ω–æ –∏ –ø—Ä–∏–≤–æ–¥–∏—Ç –∫ ¬´–¥–∏—Å–∫–æ–Ω—Ç—É¬ª.

**–†–µ—à–µ–Ω–∏–µ:** –í–µ–±-–ø—Ä–æ–¥—É–∫—Ç, –∫–æ—Ç–æ—Ä—ã–π —Å—Ç—Ä–æ–∏—Ç ¬´–∫–∞—Ä—Ç—É —Ä–∞—Å–∫—Ä—ã—Ç–∏—è¬ª: –∫–∞–∫–∏–µ –∫–ª—é—á–µ–≤—ã–µ —ç–ª–µ–º–µ–Ω—Ç—ã –¥–∞–Ω–Ω—ã—Ö –∑–∞—è–≤–ª–µ–Ω—ã, —á—Ç–æ –æ—Ç—Å—É—Ç—Å—Ç–≤—É–µ—Ç, –≥–¥–µ –µ—Å—Ç—å –Ω–µ—Å–æ—Å—Ç—ã–∫–æ–≤–∫–∏.

**Wedge:** –ì–µ–Ω–µ—Ä–∞—Ç–æ—Ä ¬´10 –≤–æ–ø—Ä–æ—Å–æ–≤ –º–µ–Ω–µ–¥–∂–º–µ–Ω—Ç—É¬ª + Opacity Score –ø–æ –æ–¥–Ω–æ–π –∫–æ–º–ø–∞–Ω–∏–∏.

**–°–∏–Ω–µ—Ä–≥–∏—è:** –î–æ–ø–æ–ª–Ω—è–µ—Ç Pipeline Briefs –∞–Ω–∞–ª–∏–∑–æ–º –∫–∞—á–µ—Å—Ç–≤–∞ —Ä–∞—Å–∫—Ä—ã—Ç–∏—è.

---

#### 3.1.4 Drug Success DD Copilot
**ID:** `idea_biotech_due_diligence_prob`

**–ü—Ä–æ–±–ª–µ–º–∞:** DCF –≤ biotech –≤–æ—Å–ø—Ä–∏–Ω–∏–º–∞–µ—Ç—Å—è –∫–∞–∫ —Å—É–±—ä–µ–∫—Ç–∏–≤–Ω—ã–π; —Ñ–æ–∫—É—Å —Å–º–µ—â–∞–µ—Ç—Å—è –Ω–∞ due diligence –ø–æ –≤–µ—Ä–æ—è—Ç–Ω–æ—Å—Ç–∏ —É—Å–ø–µ—Ö–∞.

**–†–µ—à–µ–Ω–∏–µ:** Copilot –¥–ª—è –∞–Ω–∞–ª–∏—Ç–∏–∫–∞: —á–µ–∫-–ª–∏—Å—Ç—ã –∏ —à–∞–±–ª–æ–Ω—ã DD, –∫–æ—Ç–æ—Ä—ã–µ —Ñ–æ—Ä–º–∏—Ä—É—é—Ç ¬´–∫–∞—Ä—Ç–æ—á–∫—É –Ω–µ–æ–ø—Ä–µ–¥–µ–ª—ë–Ω–Ω–æ—Å—Ç–µ–π¬ª –∏ —Å—Ü–µ–Ω–∞—Ä–Ω—ã–π –≤—ã–≤–æ–¥.

**Wedge:** –ì–µ–Ω–µ—Ä–∞—Ç–æ—Ä DD-–º–µ–º–æ –Ω–∞ 1‚Äì2 —Å—Ç—Ä–∞–Ω–∏—Ü—ã: ¬´—á—Ç–æ –¥–æ–ª–∂–Ω–æ –±—ã—Ç—å –ø—Ä–∞–≤–¥–æ–π, —á—Ç–æ–±—ã –∫–µ–π—Å —Å—Ä–∞–±–æ—Ç–∞–ª¬ª.

**–°–∏–Ω–µ—Ä–≥–∏—è:** Deep-dive –ø–æ—Å–ª–µ –ø–µ—Ä–≤–∏—á–Ω–æ–≥–æ Pipeline Brief.

---

### 3.2 –ö–õ–ê–°–¢–ï–†: Regulatory Intelligence

#### 3.2.1 RegIntel Copilot
**ID:** `idea_regintel_001`

**–ü—Ä–æ–±–ª–µ–º–∞:** –ù–µ–ø—Ä–µ–¥—Å–∫–∞–∑—É–µ–º–æ—Å—Ç—å –∏ –ø–µ—Ä—Å–æ–Ω–æ–∑–∞–≤–∏—Å–∏–º–æ—Å—Ç—å —Ä–µ—à–µ–Ω–∏–π –≤ CBER/FDA —Å–æ–∑–¥–∞—é—Ç –Ω–µ—Å—Ç–∞–±–∏–ª—å–Ω–æ—Å—Ç—å.

**–†–µ—à–µ–Ω–∏–µ:** –í–µ–±-–ø—Ä–æ–¥—É–∫—Ç —Å ¬´—Ä–µ–≥—É–ª—è—Ç–æ—Ä–Ω—ã–º —Å–∏—Ç—É–∞—Ü–∏–æ–Ω–Ω—ã–º —Ü–µ–Ω—Ç—Ä–æ–º¬ª:
1. –°—Ç—Ä—É–∫—Ç—É—Ä–∏—Ä–æ–≤–∞–Ω–Ω–∞—è –ª–µ–Ω—Ç–∞ —Å–æ–±—ã—Ç–∏–π/—Å–∏–≥–Ω–∞–ª–æ–≤ –ø–æ —Ä—É–∫–æ–≤–æ–¥—Å—Ç–≤—É FDA/CBER
2. –ö–∞—Ä—Ç–æ—á–∫–∏ ¬´—á—Ç–æ —ç—Ç–æ –º–æ–∂–µ—Ç –∑–Ω–∞—á–∏—Ç—å¬ª
3. –ì–µ–Ω–µ—Ä–∞—Ç–æ—Ä —Å–ø–∏—Å–∫–æ–≤ –≤–æ–ø—Ä–æ—Å–æ–≤ –¥–ª—è –ø–æ–¥–≥–æ—Ç–æ–≤–∫–∏ –∫ –≤—Å—Ç—Ä–µ—á–∞–º —Å FDA

**Wedge:** –ï–∂–µ–Ω–µ–¥–µ–ª—å–Ω—ã–π ¬´CBER volatility brief¬ª + –ø–µ—Ä—Å–æ–Ω–∞–ª—å–Ω–∞—è —Å—Ç—Ä–∞–Ω–∏—Ü–∞ –∫–æ–º–ø–∞–Ω–∏–∏.

**–°–∏–Ω–µ—Ä–≥–∏—è:** Regulatory context –¥–ª—è Pipeline changes.

---

#### 3.2.2 Regulatory Uncertainty Radar (CBER)
**ID:** `idea_doc_c2f93887fd12_4_02`

**–ü—Ä–æ–±–ª–µ–º–∞:** –ù–µ–æ–ø—Ä–µ–¥–µ–ª—ë–Ω–Ω–æ—Å—Ç—å –≤ —Ç–æ–º, –Ω–∞—Å–∫–æ–ª—å–∫–æ –≥–∏–±–∫–æ CBER –±—É–¥–µ—Ç –ø–æ–¥—Ö–æ–¥–∏—Ç—å –∫ gene therapy.

**–†–µ—à–µ–Ω–∏–µ:** –°–µ—Ä–≤–∏—Å –º–æ–Ω–∏—Ç–æ—Ä–∏–Ω–≥–∞: —Å—Ç—Ä—É–∫—Ç—É—Ä–∏—Ä—É–µ—Ç –ø—É–±–ª–∏—á–Ω—ã–µ —Å–æ–±—ã—Ç–∏—è –≤ –≤–∏–¥–µ —Ç–∞–π–º–ª–∞–π–Ω–∞ –∏ ¬´–º–∞—Ç—Ä–∏—Ü—ã –≤–æ–ø—Ä–æ—Å–æ–≤¬ª.

**Wedge:** –ï–∂–µ–Ω–µ–¥–µ–ª—å–Ω—ã–π email ¬´—á—Ç–æ –º–æ–∂–µ—Ç –ø—Ä–æ—è—Å–Ω–∏—Ç—å –ø–æ–∑–∏—Ü–∏—é CBER –≤ –±–ª–∏–∂–∞–π—à–∏–µ –º–µ—Å—è—Ü—ã¬ª.

**–°–∏–Ω–µ—Ä–≥–∏—è:** –°–ø–µ—Ü–∏–∞–ª–∏–∑–∏—Ä–æ–≤–∞–Ω–Ω—ã–π —Ç—Ä–µ–∫–µ—Ä –¥–ª—è gene therapy –ø—Ä–æ–≥—Ä–∞–º–º.

---

#### 3.2.3 FDA Signal Map
**ID:** `idea_fda_signalmap_003`

**–ü—Ä–æ–±–ª–µ–º–∞:** –í–Ω—É—Ç—Ä–∏ FDA –∏–¥—É—Ç ¬´raging debates¬ª, —Å–º–µ–Ω–∞ —Ä—É–∫–æ–≤–æ–¥–∏—Ç–µ–ª–µ–π –º–æ–∂–µ—Ç —Ä–µ–∑–∫–æ –º–µ–Ω—è—Ç—å —Ä–µ—à–µ–Ω–∏—è.

**–†–µ—à–µ–Ω–∏–µ:** –ü—Ä–æ–¥—É–∫—Ç, –∫–æ—Ç–æ—Ä—ã–π –ø—Ä–µ–≤—Ä–∞—â–∞–µ—Ç —Ä–∞–∑—Ä–æ–∑–Ω–µ–Ω–Ω—ã–µ —Å–∏–≥–Ω–∞–ª—ã –≤ —Å—Ç—Ä—É–∫—Ç—É—Ä—É: —Ç–∞–π–º–ª–∞–π–Ω —Å–æ–±—ã—Ç–∏–π, —Ç–µ–≥–∏, –∑–∞–º–µ—Ç–∫–∏ ¬´—á—Ç–æ —ç—Ç–æ –º–æ–∂–µ—Ç –∑–Ω–∞—á–∏—Ç—å¬ª.

**Wedge:** –ï–∂–µ–Ω–µ–¥–µ–ª—å–Ω—ã–π ¬´FDA Mixed Signals Brief¬ª + –∏–Ω—Ç–µ—Ä–∞–∫—Ç–∏–≤–Ω—ã–π —Ç–∞–π–º–ª–∞–π–Ω.

**–°–∏–Ω–µ—Ä–≥–∏—è:** ¬´–ü–æ–≥–æ–¥–∞¬ª –¥–ª—è —Ä–µ–≥—É–ª—è—Ç–æ—Ä–Ω—ã—Ö –æ–∂–∏–¥–∞–Ω–∏–π –≤ Platform.

---

#### 3.2.4 Policy Risk Radar
**ID:** `idea_policy_risk_radar_001`

**–ü—Ä–æ–±–ª–µ–º–∞:** –ò–Ω–≤–µ—Å—Ç–æ—Ä—ã –∏ –∫–æ–º–∞–Ω–¥—ã –Ω–µ –ø–æ–Ω–∏–º–∞—é—Ç, –±—É–¥–µ—Ç –ª–∏ –ø–æ–ª–∏—Ç–∏–∫–∞ –ø—Ä–æ-—Ñ–∞—Ä–º–∞ –∏–ª–∏ –∞–Ω—Ç–∏-—Ñ–∞—Ä–º–∞; —Å–ª—É—à–∞–Ω–∏—è –¥–∞—é—Ç –º–∞–ª–æ —è—Å–Ω–æ—Å—Ç–∏.

**–†–µ—à–µ–Ω–∏–µ:** –í–µ–±-–ø—Ä–æ–¥—É–∫—Ç —Å ¬´—Å—Ü–µ–Ω–∞—Ä–Ω—ã–º –∫–æ–Ω—Å—Ç—Ä—É–∫—Ç–æ—Ä–æ–º¬ª: –ø–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª—å –≤—ã–±–∏—Ä–∞–µ—Ç –∫–æ–Ω—Ç–µ–∫—Å—Ç, —Å–∏—Å—Ç–µ–º–∞ —Ñ–æ—Ä–º–∏—Ä—É–µ—Ç –Ω–∞–±–æ—Ä —Å—Ü–µ–Ω–∞—Ä–∏–µ–≤, –∫–∞—Ä—Ç—É —Ä–∏—Å–∫–æ–≤ –∏ –æ–ø–µ—Ä–∞—Ü–∏–æ–Ω–Ω—ã–µ —Ä–µ–∫–æ–º–µ–Ω–¥–∞—Ü–∏–∏.

**Wedge:** –ï–∂–µ–Ω–µ–¥–µ–ª—å–Ω—ã–π ¬´Policy Brief –¥–ª—è biotech¬ª –≤ –≤–∏–¥–µ 1 —Å—Ç—Ä–∞–Ω–∏—Ü—ã + –∏–Ω—Ç–µ—Ä–∞–∫—Ç–∏–≤–Ω–∞—è —Ç–∞–±–ª–∏—Ü–∞ —Å—Ü–µ–Ω–∞—Ä–∏–µ–≤.

**–°–∏–Ω–µ—Ä–≥–∏—è:** Macro context layer –¥–ª—è –≤—Å–µ—Ö Pipeline/Catalyst –¥–∞–Ω–Ω—ã—Ö.

---

#### 3.2.5 PDUFA Delay Risk Radar
**ID:** `idea_pdufa_delay_risk_radar`

**–ü—Ä–æ–±–ª–µ–º–∞:** –ü—É–±–ª–∏—á–Ω—ã–µ –¥–∞—Ç—ã –º–æ–≥—É—Ç –Ω–µ —Å–æ–±–ª—é–¥–∞—Ç—å—Å—è; –≤ —Å–ª–æ–∂–Ω—ã—Ö –æ–±–∑–æ—Ä–∞—Ö –≤–æ–∑–º–æ–∂–Ω—ã –∑–∞–¥–µ—Ä–∂–∫–∏ PDUFA.

**–†–µ—à–µ–Ω–∏–µ:** –í–Ω—É—Ç—Ä–µ–Ω–Ω–∏–π ¬´—Ä–∞–¥–∞—Ä¬ª –¥–ª—è –ø—Ä–æ–≥—Ä–∞–º–º: –∫–∞–ª–µ–Ω–¥–∞—Ä—å —Ä–µ–≥—É–ª—è—Ç–æ—Ä–Ω—ã—Ö –≤–µ—Ö + –∂—É—Ä–Ω–∞–ª –Ω–µ–æ–ø—Ä–µ–¥–µ–ª–µ–Ω–Ω–æ—Å—Ç–µ–π.

**Wedge:** –õ–µ–≥–∫–∏–π ¬´PDUFA uncertainty log¬ª —Å –≥–æ—Ç–æ–≤—ã–º–∏ –ø–æ–ª—è–º–∏ –∏ –µ–∂–µ–Ω–µ–¥–µ–ª—å–Ω—ã–º –∞–≤—Ç–æ-—Ä–µ–ø–æ—Ä—Ç–æ–º.

**–°–∏–Ω–µ—Ä–≥–∏—è:** –î–µ—Ç–∞–ª–∏–∑–∞—Ü–∏—è –¥–ª—è Catalyst Radar —Å regulatory focus.

---

### 3.3 –ö–õ–ê–°–¢–ï–†: Sentiment & Market Intelligence

#### 3.3.1 Biotech Sentiment Radar
**ID:** `idea_af75_biotech_sentiment_radar`

**–ü—Ä–æ–±–ª–µ–º–∞:** –í –±–∏–æ—Ç–µ—Ö–µ —Ñ–∏–∫—Å–∏—Ä—É–µ—Ç—Å—è —Å–∏–ª—å–Ω—ã–π –Ω–µ–≥–∞—Ç–∏–≤–Ω—ã–π —Å–µ–Ω—Ç–∏–º–µ–Ω—Ç –∏ ¬´winter's here¬ª. –°–ª–æ–∂–Ω–æ –±—ã—Å—Ç—Ä–æ –∏–Ω—Ç–µ—Ä–ø—Ä–µ—Ç–∏—Ä–æ–≤–∞—Ç—å, —á—Ç–æ –∏–º–µ–Ω–Ω–æ —É—Ö—É–¥—à–∏–ª–æ—Å—å/—É–ª—É—á—à–∏–ª–æ—Å—å.

**–†–µ—à–µ–Ω–∏–µ:** –û–Ω–ª–∞–π–Ω-–¥–∞—à–±–æ—Ä–¥ —Å ¬´—Å–µ–Ω—Ç–∏–º–µ–Ω—Ç-–∏–Ω–¥–∏–∫–∞—Ç–æ—Ä–∞–º–∏¬ª:
1. –°–µ–∫—Ç–æ—Ä–∞–ª—å–Ω—ã–π –ø–µ—Å—Å–∏–º–∏–∑–º
2. –†–∞–∑–≤–æ—Ä–æ—Ç –Ω–∞—Å—Ç—Ä–æ–µ–Ω–∏–π
3. –ú–∞–∫—Ä–æ/–ø–æ–ª–∏—Ç–∏—á–µ—Å–∫–∞—è –Ω–µ–æ–ø—Ä–µ–¥–µ–ª—ë–Ω–Ω–æ—Å—Ç—å
4. –°–∏–≥–Ω–∞–ª—ã –æ—Ç—Ç–æ–∫–æ–≤ –∫–∞–ø–∏—Ç–∞–ª–∞

**Wedge:** –ë–µ—Å–ø–ª–∞—Ç–Ω—ã–π –ø—É–±–ª–∏—á–Ω—ã–π ¬´Biotech Winter Index¬ª + —Ä–∞—Å—Å—ã–ª–∫–∞ –Ω–∞ 1 —Å—Ç—Ä–∞–Ω–∏—Ü—É.

**–°–∏–Ω–µ—Ä–≥–∏—è:** Context layer: ¬´–∫–∞–∫–æ–π —Å–µ–π—á–∞—Å —Ä—ã–Ω–æ–∫¬ª –¥–ª—è –∏–Ω—Ç–µ—Ä–ø—Ä–µ—Ç–∞—Ü–∏–∏ Pipeline —Å–æ–±—ã—Ç–∏–π.

---

#### 3.3.2 Biotech Sentiment & Financing Radar
**ID:** `idea_biotech_sentiment_ma_radar`

**–ü—Ä–æ–±–ª–µ–º–∞:** –°–µ–Ω—Ç–∏–º–µ–Ω—Ç –≤ biotech –º–µ–Ω—è–µ—Ç—Å—è, IPO –Ω–µ—Ç, –Ω–æ secondaries –ø—Ä–æ—Ö–æ–¥—è—Ç —Ö–æ—Ä–æ—à–æ; M&A –µ—Å—Ç—å, –Ω–æ –ø—Ä–µ–º–∏–∏ ¬´underwhelming¬ª.

**–†–µ—à–µ–Ω–∏–µ:** –í–µ–±-–ø—Ä–æ–¥—É–∫—Ç —Å –¥–∞—à–±–æ—Ä–¥–∞–º–∏:
1. –ò–Ω–¥–∏–∫–∞—Ç–æ—Ä—ã ¬´risk-on/risk-off¬ª –¥–ª—è biotech
2. –¢—Ä–µ–∫–µ—Ä —Ñ–∏–Ω–∞–Ω—Å–∏—Ä–æ–≤–∞–Ω–∏–π (—Ñ–æ–∫—É—Å –Ω–∞ secondaries)
3. –¢—Ä–µ–∫–µ—Ä M&A-–∞–∫—Ç–∏–≤–Ω–æ—Å—Ç–∏ –∏ —Ä–∞—Å–ø—Ä–µ–¥–µ–ª–µ–Ω–∏—è –ø—Ä–µ–º–∏–π

**Wedge:** –ú–∏–Ω–∏-—Ä–∞–¥–∞—Ä ¬´Biotech vs S&P + Financing Pulse¬ª.

**–°–∏–Ω–µ—Ä–≥–∏—è:** Market context –¥–ª—è Deal Intelligence layer.

---

### 3.4 –ö–õ–ê–°–¢–ï–†: Clinical Data Intelligence

#### 3.4.1 SignalSkeptic: QA –¥–ª—è –∫–ª–∏–Ω–∏—á–µ—Å–∫–∏—Ö –¥–∞–Ω–Ω—ã—Ö
**ID:** `idea_trial_signal_skeptic`

**–ü—Ä–æ–±–ª–µ–º–∞:** –í–æ–∫—Ä—É–≥ –∫–ª–∏–Ω–∏—á–µ—Å–∫–∏—Ö –¥–∞–Ω–Ω—ã—Ö –º–æ–≥—É—Ç –≤–æ–∑–Ω–∏–∫–∞—Ç—å –º–∞—Å—Å–æ–≤—ã–µ —Å–æ–º–Ω–µ–Ω–∏—è: —É—á–∞—Å—Ç–Ω–∏–∫–∏ –Ω–µ –ø–æ–Ω–∏–º–∞—é—Ç, –¥–æ—Å—Ç–∞—Ç–æ—á–Ω–æ –ª–∏ –¥–∞–Ω–Ω—ã–µ —Ö–æ—Ä–æ—à–∏.

**–†–µ—à–µ–Ω–∏–µ:** –í–µ–±-–∏–Ω—Å—Ç—Ä—É–º–µ–Ω—Ç –¥–ª—è ¬´data narrative QA¬ª: –∑–∞–≥—Ä—É–∑–∫–∞ –∫–ª—é—á–µ–≤—ã—Ö —á–∏—Å–µ–ª, –ø–æ—Å—Ç—Ä–æ–µ–Ω–∏–µ —Å—Ç–∞–Ω–¥–∞—Ä—Ç–Ω—ã—Ö –≥—Ä–∞—Ñ–∏–∫–æ–≤, —á–µ–∫-–ª–∏—Å—Ç—ã –≤–æ–ø—Ä–æ—Å–æ–≤, –∂—É—Ä–Ω–∞–ª ¬´—Å–æ–º–Ω–µ–Ω–∏–π¬ª —Å –≥–µ–Ω–µ—Ä–∞—Ü–∏–µ–π Q&A.

**Wedge:** ¬´Call-prep pack¬ª –∑–∞ 30 –º–∏–Ω—É—Ç: —Å–ø–∏—Å–æ–∫ –ø–æ—Ç–µ–Ω—Ü–∏–∞–ª—å–Ω—ã—Ö –≤–æ–ø—Ä–æ—Å–æ–≤ –∏ —Å–ª–∞–±—ã—Ö –º–µ—Å—Ç.

**–°–∏–Ω–µ—Ä–≥–∏—è:** Deep-dive –¥–ª—è –∫–æ–º–ø–∞–Ω–∏–π –ø–æ—Å–ª–µ data release ‚Üí Pipeline Brief.

---

#### 3.4.2 Readout Radar
**ID:** `idea_readout_radar_neuro_onco_003`

**–ü—Ä–æ–±–ª–µ–º–∞:** –û–∂–∏–¥–∞–µ—Ç—Å—è ¬´–ø—É—á–æ–∫¬ª –±–ª–∏–∂–∞–π—à–∏—Ö –∫–ª–∏–Ω–∏—á–µ—Å–∫–∏—Ö readouts; –≤–∞–∂–Ω–æ —Å–∏—Å—Ç–µ–º–Ω–æ –æ—Ç—Å–ª–µ–∂–∏–≤–∞—Ç—å —Å–æ–±—ã—Ç–∏—è –∏ —Ñ–∏–∫—Å–∏—Ä–æ–≤–∞—Ç—å –æ–∂–∏–¥–∞–Ω–∏—è –¥–æ –ø—É–±–ª–∏–∫–∞—Ü–∏–∏.

**–†–µ—à–µ–Ω–∏–µ:** –ü–ª–∞—Ç—Ñ–æ—Ä–º–∞ –∫–∞—Ä—Ç–æ—á–µ–∫ readout: –¥–∞—Ç–∞/—Ç–∏–ø —Å–æ–±—ã—Ç–∏—è, ¬´pre-readout expectations¬ª, —Ä–∏—Å–∫–∏ –∏–Ω—Ç–µ—Ä–ø—Ä–µ—Ç–∞—Ü–∏–∏, ¬´post-readout debrief¬ª.

**Wedge:** –ü—É–±–ª–∏—á–Ω—ã–π –∫–∞–ª–µ–Ω–¥–∞—Ä—å readouts + —à–∞–±–ª–æ–Ω ¬´Expectation Sheet¬ª –≤ –æ–¥–∏–Ω –∫–ª–∏–∫.

**–°–∏–Ω–µ—Ä–≥–∏—è:** –î–µ—Ç–∞–ª–∏–∑–∞—Ü–∏—è –¥–ª—è Catalyst Radar —Å clinical focus.

---

#### 3.4.3 Safety Signal Notebook
**ID:** `idea_doc_433066c16b44_b3_03`

**–ü—Ä–æ–±–ª–µ–º–∞:** –°—É—â–µ—Å—Ç–≤–µ–Ω–Ω—ã–µ safety-—Å–∏–≥–Ω–∞–ª—ã —É—Å–ª–æ–∂–Ω—è—é—Ç –∏–Ω—Ç–µ—Ä–ø—Ä–µ—Ç–∞—Ü–∏—é benefit/risk.

**–†–µ—à–µ–Ω–∏–µ:** –ü—Ä–æ–¥—É–∫—Ç –¥–ª—è —Ñ–∏–∫—Å–∞—Ü–∏–∏ safety-—Å–æ–±—ã—Ç–∏–π, —Å–≤—è–∑–∏ —Å –∫–ª—é—á–µ–≤—ã–º–∏ —Ç–µ–∑–∏—Å–∞–º–∏ benefit/risk, –ø–æ–¥–≥–æ—Ç–æ–≤–∫–∏ Q&A.

**Wedge:** –ë–µ—Å–ø–ª–∞—Ç–Ω—ã–π —à–∞–±–ª–æ–Ω ¬´Benefit/Risk Q&A¬ª + –≥–µ–Ω–µ—Ä–∞—Ç–æ—Ä ¬´–Ω–µ—É–¥–æ–±–Ω—ã—Ö –≤–æ–ø—Ä–æ—Å–æ–≤¬ª.

**–°–∏–Ω–µ—Ä–≥–∏—è:** Safety layer –¥–ª—è Pipeline Briefs.

---

#### 3.4.4 Approvability Radar
**ID:** `idea_doc_433066c16b44_b3_01`

**–ü—Ä–æ–±–ª–µ–º–∞:** –ö–æ–º–∞–Ω–¥—ã –∏ –∏–Ω–≤–µ—Å—Ç–æ—Ä—ã —Å—Ç–∞–ª–∫–∏–≤–∞—é—Ç—Å—è —Å –ø—Ä–æ–≤–∞–ª–∞–º–∏ –∏–∑-–∑–∞ –Ω–µ–¥–∏—Ñ—Ñ–µ—Ä–µ–Ω—Ü–∏—Ä–æ–≤–∞–Ω–Ω–æ—Å—Ç–∏, –Ω–µ–¥–æ—Å—Ç–∞—Ç–æ—á–Ω–æ–π —Å—Ç–∞—Ç–∏—Å—Ç–∏—á–µ—Å–∫–æ–π –∑–Ω–∞—á–∏–º–æ—Å—Ç–∏.

**–†–µ—à–µ–Ω–∏–µ:** –í–µ–±-–ø—Ä–æ–¥—É–∫—Ç, –∫–æ—Ç–æ—Ä—ã–π –ø—Ä–µ–≤—Ä–∞—â–∞–µ—Ç —Ä–∞–∑—Ä–æ–∑–Ω–µ–Ω–Ω—ã–µ —Ç–µ–∑–∏—Å—ã –≤:
1. –ö–∞—Ä—Ç—É —Ä–∏—Å–∫–æ–≤ ¬´approvability¬ª
2. –°–ø–∏—Å–æ–∫ –∫—Ä–∏—Ç–∏—á–µ—Å–∫–∏—Ö –≤–æ–ø—Ä–æ—Å–æ–≤ –æ—Ç —Ä–µ–≥—É–ª—è—Ç–æ—Ä–∞
3. –®–∞–±–ª–æ–Ω—ã –æ—Ç–≤–µ—Ç–æ–≤ –∏ ¬´–Ω–∞—Ä—Ä–∞—Ç–∏–≤¬ª

**Wedge:** –ë–µ—Å–ø–ª–∞—Ç–Ω—ã–π ¬´Approvability Checklist¬ª + –≥–µ–Ω–µ—Ä–∞—Ç–æ—Ä —Å–ø–∏—Å–∫–∞ –≤–æ–ø—Ä–æ—Å–æ–≤.

**–°–∏–Ω–µ—Ä–≥–∏—è:** Pre-approval analysis –¥–ª—è Pipeline changes.

---

### 3.5 –ö–õ–ê–°–¢–ï–†: Deal Intelligence

#### 3.5.1 De-risked Dealflow OS
**ID:** `idea_derisked_dealflow_os`

**–ü—Ä–æ–±–ª–µ–º–∞:** –î–∞–≤–ª–µ–Ω–∏–µ –Ω–∞–π—Ç–∏ ¬´—Å–ª–µ–¥—É—é—â—É—é –ª–∏–Ω–∏—é –ø—Ä–æ–¥–∞–∂¬ª –≤–∑–∞–º–µ–Ω –∑—Ä–µ–ª–æ–≥–æ —Ñ—Ä–∞–Ω—á–∞–π–∑–∞; —Ç—Ä–µ–Ω–¥ –Ω–∞ —Å–æ–∫—Ä–∞—â–µ–Ω–∏–µ –≤–Ω—É—Ç—Ä–µ–Ω–Ω–µ–≥–æ R&D –∏ –ø–æ–∫—É–ø–∫—É de-risked –ø—Ä–æ–¥—É–∫—Ç–æ–≤.

**–†–µ—à–µ–Ω–∏–µ:** SaaS-¬´–æ–ø–µ—Ä–∞—Ü–∏–æ–Ω–∫–∞¬ª –¥–ª—è BD: –ø–∞–π–ø–ª–∞–π–Ω –≤–æ–∑–º–æ–∂–Ω–æ—Å—Ç–µ–π, —Å—Ç–∞—Ç—É—Å—ã, —á–µ–∫-–ª–∏—Å—Ç—ã de-risking, –≥–µ–Ω–µ—Ä–∞—Ü–∏—è one-pager.

**Wedge:** –®–∞–±–ª–æ–Ω—ã –∏ —á–µ–∫-–ª–∏—Å—Ç—ã ¬´de-risking¬ª + –ø—Ä–æ—Å—Ç–æ–π –ø–∞–π–ø–ª–∞–π–Ω –¥–ª—è 1 –∫–æ–º–∞–Ω–¥—ã.

**–°–∏–Ω–µ—Ä–≥–∏—è:** BD workflow –Ω–∞ –æ—Å–Ω–æ–≤–µ Pipeline Gap Radar —Å–∏–≥–Ω–∞–ª–æ–≤.

---

#### 3.5.2 Royalty/Structured Deal Builder
**ID:** `idea_royalty_deal_structurer`

**–ü—Ä–æ–±–ª–µ–º–∞:** –ù–∞ —Ñ–æ–Ω–µ –¥–µ—Ñ–∏—Ü–∏—Ç–∞ –∫–∞–ø–∏—Ç–∞–ª–∞ –∫–æ–º–ø–∞–Ω–∏–∏ –∏—â—É—Ç –∞–ª—å—Ç–µ—Ä–Ω–∞—Ç–∏–≤–Ω—ã–µ –∏—Å—Ç–æ—á–Ω–∏–∫–∏ —Ñ–∏–Ω–∞–Ω—Å–∏—Ä–æ–≤–∞–Ω–∏—è (—Ä–æ—è–ª—Ç–∏ + –¥–æ–ª–≥).

**–†–µ—à–µ–Ω–∏–µ:** –í–µ–±-–ø—Ä–∏–ª–æ–∂–µ–Ω–∏–µ —Å –∫–æ–Ω—Å—Ç—Ä—É–∫—Ç–æ—Ä–æ–º term sheet: –ø–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª—å –∑–∞–¥–∞—ë—Ç –ø–∞—Ä–∞–º–µ—Ç—Ä—ã, –ø–æ–ª—É—á–∞–µ—Ç —Å—Ä–∞–≤–Ω–µ–Ω–∏–µ —Å—Ü–µ–Ω–∞—Ä–∏–µ–≤ –∏ deal memo.

**Wedge:** –ì–µ–Ω–µ—Ä–∞—Ç–æ—Ä 2-—Å—Ç—Ä–∞–Ω–∏—á–Ω–æ–≥–æ deal memo + —Ç–∞–±–ª–∏—Ü–∞ —Å—Ä–∞–≤–Ω–µ–Ω–∏—è 3 –≤–∞—Ä–∏–∞–Ω—Ç–æ–≤ —Å—Ç—Ä—É–∫—Ç—É—Ä—ã.

**–°–∏–Ω–µ—Ä–≥–∏—è:** Deal structuring tool –¥–ª—è –∫–æ–º–ø–∞–Ω–∏–π –≤ Platform.

---

#### 3.5.3 China-to-US Regulatory Readiness Kit
**ID:** `idea_china_asset_regulatory_readiness`

**–ü—Ä–æ–±–ª–µ–º–∞:** FDA –æ—Ç–∫–ª–æ–Ω—è–ª–∞ –ø—Ä–µ–ø–∞—Ä–∞—Ç –∏–∑-–∑–∞ –∫—Ä–∏—Ç–∏–∫–∏ –¥–∞–Ω–Ω—ã—Ö —Ç–æ–ª—å–∫–æ –∏–∑ –ö–∏—Ç–∞—è.

**–†–µ—à–µ–Ω–∏–µ:** –í–µ–±-–∏–Ω—Å—Ç—Ä—É–º–µ–Ω—Ç –¥–ª—è BD/clin/reg teams: –∑–∞–≥—Ä—É–∑–∫–∞ data package ‚Üí ¬´evidence map¬ª + –∞–≤—Ç–æ–º–∞—Ç–∏—á–µ—Å–∫–∏–π —Å–ø–∏—Å–æ–∫ —Ä–µ–≥—É–ª—è—Ç–æ—Ä–Ω—ã—Ö –≤–æ–ø—Ä–æ—Å–æ–≤.

**Wedge:** –ë–µ—Å–ø–ª–∞—Ç–Ω—ã–π ¬´Regulatory Red Flag Scanner¬ª –¥–ª—è 5‚Äì10 —Å—Ç—Ä–∞–Ω–∏—Ü data summary.

**–°–∏–Ω–µ—Ä–≥–∏—è:** Due diligence layer –¥–ª—è cross-border deals.

---

## 4. –ê–†–•–ò–¢–ï–ö–¢–£–†–ê –ü–†–û–î–£–ö–¢–ê

### 4.1 –ú–æ–¥—É–ª—å–Ω–∞—è —Å—Ç—Ä—É–∫—Ç—É—Ä–∞

```
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ                  BIOTECH INTELLIGENCE HUB                   ‚îÇ
‚îú‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î§
‚îÇ                                                             ‚îÇ
‚îÇ  ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê  ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê  ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê ‚îÇ
‚îÇ  ‚îÇ PIPELINE LAYER  ‚îÇ  ‚îÇ CATALYST LAYER  ‚îÇ  ‚îÇ CONTEXT     ‚îÇ ‚îÇ
‚îÇ  ‚îÇ                 ‚îÇ  ‚îÇ                 ‚îÇ  ‚îÇ LAYERS      ‚îÇ ‚îÇ
‚îÇ  ‚îÇ ‚Ä¢ Pipeline      ‚îÇ  ‚îÇ ‚Ä¢ Catalyst      ‚îÇ  ‚îÇ             ‚îÇ ‚îÇ
‚îÇ  ‚îÇ   Briefs        ‚îÇ  ‚îÇ   Radar         ‚îÇ  ‚îÇ ‚Ä¢ Sentiment ‚îÇ ‚îÇ
‚îÇ  ‚îÇ ‚Ä¢ Data-First    ‚îÇ  ‚îÇ ‚Ä¢ Readout       ‚îÇ  ‚îÇ ‚Ä¢ Regulatory‚îÇ ‚îÇ
‚îÇ  ‚îÇ   IR Kit        ‚îÇ  ‚îÇ   Radar         ‚îÇ  ‚îÇ ‚Ä¢ Policy    ‚îÇ ‚îÇ
‚îÇ  ‚îÇ ‚Ä¢ Launch        ‚îÇ  ‚îÇ ‚Ä¢ PDUFA         ‚îÇ  ‚îÇ ‚Ä¢ M&A/Deal  ‚îÇ ‚îÇ
‚îÇ  ‚îÇ   Briefs        ‚îÇ  ‚îÇ   Tracker       ‚îÇ  ‚îÇ             ‚îÇ ‚îÇ
‚îÇ  ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò  ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò  ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò ‚îÇ
‚îÇ           ‚îÇ                    ‚îÇ                   ‚îÇ        ‚îÇ
‚îÇ           ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò        ‚îÇ
‚îÇ                            ‚îÇ                                ‚îÇ
‚îÇ  ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚ñº‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê ‚îÇ
‚îÇ  ‚îÇ              UNIFIED COMPANY PROFILE                   ‚îÇ ‚îÇ
‚îÇ  ‚îÇ                                                        ‚îÇ ‚îÇ
‚îÇ  ‚îÇ  Company ‚Üí Pipeline Changes ‚Üí Catalysts ‚Üí Context      ‚îÇ ‚îÇ
‚îÇ  ‚îÇ         ‚Üí Regulatory Status ‚Üí Deal Signals             ‚îÇ ‚îÇ
‚îÇ  ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò ‚îÇ
‚îÇ                                                             ‚îÇ
‚îÇ  ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê‚îÇ
‚îÇ  ‚îÇ OUTPUT FORMATS: PDF | Slack | Email | Notion | API     ‚îÇ‚îÇ
‚îÇ  ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
```

### 4.2 –ü–æ—Ç–æ–∫–∏ –¥–∞–Ω–Ω—ã—Ö

```
INPUT SOURCES                    PROCESSING                 OUTPUT
‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ                   ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ                 ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ

Earnings Transcripts ‚îÄ‚îÄ‚îê
                       ‚îÇ
Press Releases ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚Üí LLM Pipeline ‚îÄ‚îÄ‚Üí Structured   ‚îÄ‚îÄ‚Üí Pipeline Brief
                       ‚îÇ                      Extraction
SEC Filings ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î§
                       ‚îÇ
Company Updates ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò

                       ‚îå‚îÄ‚îÄ‚Üí Change Detection ‚îÄ‚îÄ‚Üí Change Log ‚îÄ‚îÄ‚Üí Alerts
                       ‚îÇ
Calendar Events ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚Üí Timeline Builder ‚îÄ‚îÄ‚Üí Catalyst Cards
                       ‚îÇ
News/Signals ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚Üí Context Enrichment ‚îÄ‚îÄ‚Üí Context Layers
```

### 4.3 User Journeys

**Journey 1: Analyst Coverage**
```
New Company ‚Üí Pipeline Brief ‚Üí Catalyst Radar ‚Üí Watchlist ‚Üí Weekly Updates
```

**Journey 2: Quarterly Review**
```
Earnings Season ‚Üí Batch Pipeline Briefs ‚Üí Change Summary ‚Üí Portfolio Update
```

**Journey 3: Due Diligence**
```
Target Company ‚Üí Deep Pipeline Brief ‚Üí Regulatory Context ‚Üí DD Questions ‚Üí Report
```

**Journey 4: BD/Outreach**
```
Pipeline Gap Alert ‚Üí Target Identification ‚Üí Outreach Pack ‚Üí Deal Tracking
```

---

## 5. –¶–ï–õ–ï–í–ê–Ø –ê–£–î–ò–¢–û–†–ò–Ø

### 5.1 –ü–µ—Ä–≤–∏—á–Ω—ã–µ —Å–µ–≥–º–µ–Ω—Ç—ã

| –°–µ–≥–º–µ–Ω—Ç | –†–æ–ª—å | –ö–ª—é—á–µ–≤–∞—è –ø–æ—Ç—Ä–µ–±–Ω–æ—Å—Ç—å | –ì–æ—Ç–æ–≤–Ω–æ—Å—Ç—å –ø–ª–∞—Ç–∏—Ç—å |
|---------|------|---------------------|-------------------|
| **Buy-side** | Portfolio managers, Analysts | –ë—ã—Å—Ç—Ä–æ –ø–æ–Ω—è—Ç—å ¬´—á—Ç–æ –∏–∑–º–µ–Ω–∏–ª–æ—Å—å¬ª | –í—ã—Å–æ–∫–∞—è |
| **Sell-side** | Research analysts | –°—Ç—Ä—É–∫—Ç—É—Ä–∏—Ä–æ–≤–∞—Ç—å coverage | –°—Ä–µ–¥–Ω—è—è |
| **Biotech IR** | IR teams | –ì–æ—Ç–æ–≤–∏—Ç—å –º–∞—Ç–µ—Ä–∏–∞–ª—ã | –í—ã—Å–æ–∫–∞—è |
| **BD teams** | BD/Strategy | –û—Ç—Å–ª–µ–∂–∏–≤–∞—Ç—å M&A —Å–∏–≥–Ω–∞–ª—ã | –í—ã—Å–æ–∫–∞—è |
| **Consultants** | Strategy consultants | –ë—ã—Å—Ç—Ä—ã–π onboarding –≤ –∫–µ–π—Å—ã | –°—Ä–µ–¥–Ω—è—è |

### 5.2 –í—Ç–æ—Ä–∏—á–Ω—ã–µ —Å–µ–≥–º–µ–Ω—Ç—ã

- **Generalist investors** (–æ–Ω–±–æ—Ä–¥–∏–Ω–≥ –≤ biotech)
- **Board members** (–∫–≤–∞—Ä—Ç–∞–ª—å–Ω—ã–µ –æ–±–∑–æ—Ä—ã)
- **Journalists** (–±—ã—Å—Ç—Ä—ã–π –∫–æ–Ω—Ç–µ–∫—Å—Ç)

---

## 6. –ö–û–ù–ö–£–†–ï–ù–¢–ù–û–ï –ü–û–ó–ò–¶–ò–û–ù–ò–†–û–í–ê–ù–ò–ï

### 6.1 –¢–µ–∫—É—â–∏–π –ª–∞–Ω–¥—à–∞—Ñ—Ç

| –ö–∞—Ç–µ–≥–æ—Ä–∏—è | –ò–≥—Ä–æ–∫–∏ | Gap |
|-----------|--------|-----|
| **Terminal/Data** | Bloomberg, FactSet, Refinitiv | –ù–µ—Ç pipeline-—Ñ–æ–∫—É—Å–∞, –Ω–µ—Ç LLM-–≤—ã–∂–∏–º–æ–∫ |
| **Biotech Data** | Evaluate, GlobalData, Citeline | –î–æ—Ä–æ–≥–æ, –Ω–µ real-time, –Ω–µ—Ç change tracking |
| **News/Alerts** | BioPharma Dive, STAT | –ù–æ–≤–æ—Å—Ç–∏, –Ω–µ —Å—Ç—Ä—É–∫—Ç—É—Ä–∏—Ä–æ–≤–∞–Ω–Ω—ã–µ –¥–∞–Ω–Ω—ã–µ |
| **AI Summarization** | Generic LLM tools | –ù–µ—Ç biotech-—Å–ø–µ—Ü–∏—Ñ–∏–∫–∏, –Ω–µ—Ç —à–∞–±–ª–æ–Ω–æ–≤ |

### 6.2 –£–Ω–∏–∫–∞–ª—å–Ω–æ–µ –ø–æ–∑–∏—Ü–∏–æ–Ω–∏—Ä–æ–≤–∞–Ω–∏–µ

```
"–ù–µ –µ—â—ë –æ–¥–∏–Ω —Ç–µ—Ä–º–∏–Ω–∞–ª –∏ –Ω–µ –µ—â—ë –æ–¥–∏–Ω AI-—Å–∞–º–º–∞—Ä–∏–∑–∞—Ç–æ—Ä.

Biotech Intelligence Hub ‚Äî —ç—Ç–æ –æ–ø–µ—Ä–∞—Ü–∏–æ–Ω–Ω–∞—è —Å–∏—Å—Ç–µ–º–∞ –¥–ª—è 
–ø—Ä–∏–Ω—è—Ç–∏—è —Ä–µ—à–µ–Ω–∏–π –≤ biotech:

‚úì Pipeline changes, –∞ –Ω–µ –æ–±—â–∏–µ —Å–∞–º–º–∞—Ä–∏
‚úì Change logs, –∞ –Ω–µ —Å—Ç–∞—Ç–∏—á–Ω—ã–µ –æ—Ç—á—ë—Ç—ã  
‚úì Actionable briefs, –∞ –Ω–µ –∏–Ω—Ñ–æ—Ä–º–∞—Ü–∏–æ–Ω–Ω—ã–π —à—É–º
‚úì Regulatory context, –∞ –Ω–µ —Ç–æ–ª—å–∫–æ –¥–∞–Ω–Ω—ã–µ
"
```

---

## 7. ROADMAP

### Phase 1: Foundation (–ú–µ—Å—è—Ü—ã 1-6)
- [ ] Pipeline Brief Generator (MVP)
- [ ] Free tier: 3 briefs/month
- [ ] Paid tier: Unlimited + history
- [ ] Public gallery of examples

### Phase 2: Calendar (–ú–µ—Å—è—Ü—ã 4-9)
- [ ] Catalyst Radar (basic)
- [ ] Watchlists + Alerts
- [ ] Integration with Pipeline Briefs

### Phase 3: Context Layers (–ú–µ—Å—è—Ü—ã 7-12)
- [ ] Regulatory Uncertainty Tracker
- [ ] Sentiment indicators
- [ ] Policy Risk Radar

### Phase 4: Deal Intelligence (–ú–µ—Å—è—Ü—ã 10-15)
- [ ] Pipeline Gap Radar
- [ ] M&A/Deal signals
- [ ] BD workflow tools

### Phase 5: Platform (–ú–µ—Å—è—Ü—ã 12-18)
- [ ] Unified Company Profiles
- [ ] Team workspaces
- [ ] API access
- [ ] Enterprise features

---

## 8. –ú–û–ù–ï–¢–ò–ó–ê–¶–ò–Ø

### 8.1 Pricing Tiers

| Tier | Price | Features |
|------|-------|----------|
| **Free** | $0 | 3 Pipeline Briefs/month, Public gallery |
| **Pro** | $99/mo | Unlimited briefs, Catalyst Radar, Alerts |
| **Team** | $299/mo | 5 seats, Shared workspaces, History |
| **Enterprise** | Custom | API, SSO, Custom integrations |

### 8.2 Revenue Streams

1. **Subscriptions** (primary)
2. **API access** (data/briefs as service)
3. **White-label** (–¥–ª—è IR firms)
4. **Events/Sponsorships** (community)

---

## 9. –ö–õ–Æ–ß–ï–í–´–ï –†–ò–°–ö–ò

| –†–∏—Å–∫ | Severity | Mitigation |
|------|----------|------------|
| LLM quality/hallucinations | High | Human-in-the-loop, confidence scores |
| Transcript availability | Medium | Multiple sources, user upload |
| Regulatory interpretation errors | High | Disclaimers, expert review layer |
| Competition from incumbents | Medium | Speed, specialization, community |
| User adoption friction | Medium | Free tier, templates, examples |

---

## 10. –°–õ–ï–î–£–Æ–©–ò–ï –®–ê–ì–ò

### Immediate (1-2 –Ω–µ–¥–µ–ª–∏)
1. [ ] –ü—Ä–æ—Ç–æ—Ç–∏–ø Pipeline Brief Generator
2. [ ] 10 —Ç–µ—Å—Ç–æ–≤—ã—Ö briefs –Ω–∞ —Ä–µ–∞–ª—å–Ω—ã—Ö —Ç—Ä–∞–Ω—Å–∫—Ä–∏–ø—Ç–∞—Ö
3. [ ] User interviews (5-10 analysts)

### Short-term (1-3 –º–µ—Å—è—Ü–∞)
1. [ ] MVP launch —Å free tier
2. [ ] Public gallery —Å 50+ –ø—Ä–∏–º–µ—Ä–∞–º–∏
3. [ ] First 100 users
4. [ ] Feedback loop –∏ –∏—Ç–µ—Ä–∞—Ü–∏–∏

### Medium-term (3-6 –º–µ—Å—è—Ü–µ–≤)
1. [ ] Catalyst Radar beta
2. [ ] First paid conversions
3. [ ] Team features
4. [ ] Regulatory layer (basic)

---

## –ü–†–ò–õ–û–ñ–ï–ù–ò–Ø

### A. –ü–æ–ª–Ω—ã–π —Å–ø–∏—Å–æ–∫ —Å–∏–Ω–µ—Ä–≥–µ—Ç–∏—á–Ω—ã—Ö –∏–¥–µ–π (150+)

–°–º. —Ñ–∞–π–ª: `synergy_analysis_earnings_call_pipeline_briefs.md`

### B. Raw –¥–∞–Ω–Ω—ã–µ TIER 1 –∏–¥–µ–π

–°–º. —Ñ–∞–π–ª: `tier1_ideas_full.jsonl`

### C. Raw –¥–∞–Ω–Ω—ã–µ TIER 2 –∏–¥–µ–π

–°–º. —Ñ–∞–π–ª: `tier2_ideas_full.jsonl`

---

*–î–æ–∫—É–º–µ–Ω—Ç —Å–æ–∑–¥–∞–Ω –¥–ª—è –≤–Ω—É—Ç—Ä–µ–Ω–Ω–µ–≥–æ –∏—Å–ø–æ–ª—å–∑–æ–≤–∞–Ω–∏—è –ø—Ä–∏ —Ä–∞–∑—Ä–∞–±–æ—Ç–∫–µ –ø—Ä–æ–¥—É–∫—Ç–æ–≤–æ–π –∫–æ–Ω—Ü–µ–ø—Ü–∏–∏*
